Actinobac Biomed Inc. is a New Brunswick, N.J.-based biopharmaceutical company led by Scott Kachlany, PhD, developing Leukothera®, a protein therapeutic that seeks out and destroys white blood cells involved in disease. Its pipeline targets multiple indications including hematological malignancies (leukemias and lymphomas), a range of autoimmune/inflammatory diseases, and HIV. The Leukothera technology was originally developed at Rutgers, The State University of New Jersey. The company will use new funding to continue its research and advance its therapeutic programs. Financial detail in the article is limited to the reported investment; no revenue or user metrics were provided. Actinobac Biomed is developing Leukothera®, a natural biologic agent that specifically targets and depletes disease-related white blood cells. The company has exclusively licensed rights to advance Leukothera as a therapeutic for hematologic malignancies (leukemias and lymphomas), a range of autoimmune and inflammatory diseases, and HIV infection. Proceeds from the recent award will fund pre-clinical studies intended to support an Investigational New Drug (IND) filing with the FDA and eventual human testing. The work is being conducted in collaboration with Rutgers researchers, including founder Scott Kachlany, PhD, and Joseph R. Bertino, M.D. Benjamin Belinka, PhD, is CEO and senior chemist. The company was originally funded by Foundation Venture Capital Group. Actinobac is based in New Brunswick, N.J. Actinobac Biomed develops pharmaceutical agents derived from the natural biologic leukotoxin (Leukothera™) that target Leukocyte Function Antigen-1 (LFA-1) on white blood cells. Its pipeline targets hematologic malignancies (leukemias and lymphomas), latent infections (HIV/AIDS and tuberculosis) and multiple autoimmune diseases. The company holds exclusive therapeutic rights to Leukothera™ under a license from the University of Medicine and Dentistry of New Jersey (UMDNJ). Actinobac intends to use the new capital to test its lead product, Leukothera, in the treatment of veterinary white blood cell diseases. The company was founded by Dr. Scott Kachlany and was established in 2009. It is based in North Brunswick, New Jersey.

Total raised

$5M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2017